Plain-English translation of NCT06313983 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether Hemay022, a new cancer-fighting medication, works better when combined with hormone-blocking drugs (like exemestane or letrozole) to treat advanced breast cancer in postmenopausal women. The study will compare this new combination against an older treatment combination (lapatinib and capecitabine) to see which one helps people live longer without their cancer getting worse. Researchers will also track how well the medication works in your body and monitor for any side effects.
Women with this type of advanced breast cancer often stop responding to standard treatments like trastuzumab (Herceptin). This trial exists to find out whether this new medication, combined with hormone therapy, can offer a better option for women whose cancer has progressed despite previous treatments.
You likely qualify if…
You likely don't qualify if…
If accepted, you will be randomly assigned to take either the new medication Hemay022 (500 mg once daily by mouth) combined with a hormone-blocking drug, or the older combination treatment. You will have regular imaging scans and check-ups to see how your cancer is responding. Your participation continues until your cancer progresses, you start a different treatment, or the trial ends — with ongoing monitoring of your health and any side effects you experience.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China